An empirical study on the sustainable growth rate of pharmaceutical companies listed in nifty 50 Mr. Kumar Arya Research Scholar, Faculty of Management Sciences, Siksha O‘ Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India. Email id: aryantripathy@yahoo.com Online published on 17 September, 2018. Abstract The pharmaceuticalindustry in India is found to be ever raising industry since 90‘s. This growth lies with the proper utilization of resources, research and development, and technology. Due to the continuous growth of such industry, it has found that the Indian economy tends to grow with the growth of other industries. The economic condition of India is growing at a faster rate globally; it is only due to the better and continuous growth of firm‘s performances. But a sustainable growth will help the firm as well as the nation to meet the competition. The steady growth will help to take a major decision on further investment for long-term growth. Similarly, the pharmaceutical industry may not be a heavy industry but their performances for last few decades are found to be rising continuously. Hence this paper will try to find out the sustainable growth rate of Pharmaceutical companies that are listed in Nifty 50. Profit margin, debt-equity ratio, returns on equity, dividend payout ratio and return on total assets to sales will be compared to sustainable growth rate to understand the impact. Top Keywords Financial Ratio, Nifty, Pharmaceutical Industry, Regression, Sustainable Growth Rate. Top |
|
Access denied
Your current subscription does not entitle you to view this content or Abstract is unavailable, the access to full-text of this Article/Journal has been denied. For Information regarding subscription please click here.
For a comprehensive list of other publications available on IJour.net please click here
or, You can subscribe other items from IJour.net (Click here to see other items list.)
Top